Compare GE Vernova Inc (GEV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Gilead Sciences, Inc. — how do they compare? GE Vernova Inc trades at $1,039.24 (market cap $269.50B), while Gilead Sciences, Inc. trades at $136.69 (market cap $168.35B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GEV | GILD | |
|---|---|---|
Market Cap | $269.50B | $168.35B |
Sector | Technology | Health |
52-Week High | $1.17K | $155.80 |
52-Week Low | $547.96 | $110.56 |
Enterprise Value | $259.17B | $191.42B |
Dividend Yield | 0.2% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,038.13, up 4.77% with strong bullish momentum. The stock shows robust fundamentals with 23% net income margin and 91% ROE, though valuation ratios appear elevated. Recent Q2 2026 earnings missed expectations, but the company maintains a massive $176 billion backlog and benefits from AI-driven power demand. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus remains strongly positive with 76% buy ratings.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, but premium valuation and execution risks on backlog conversion warrant caution. The stock offers growth exposure to power grid modernization with upside to the $1,270 consensus target, though investors should monitor quarterly execution against high expectations.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
